Skip to main content
BTAI logo

BTAI

BioXcel Therapeutics, Inc.
$0.80 -0.24 (-22.87%) At close · Jul 8
Market Cap
$24.77M
Shares
30,877,605

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$642K -71.7%
FY2025 Revenue FY2022–FY2025
Net Income
-$69.9M -17.3%
FY2025 Net Income FY2017–FY2025
Gross Margin
74.45% +69pp
FY2025 Gross Margin FY2022–FY2025
Operating Margin
-7859.97% -4892.4pp
FY2025 Operating Margin FY2022–FY2025
Diluted EPS
-$5.73 +75.6%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
-$57.62M +20%
FY2025 Operating Cash Flow FY2017–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017
$680K $642K $2.27M $1.38M $375K
$433K $164K $2.14M $1.26M $20K
$247K $478K $123K $120K $355K
74.45% 5.43% 8.7% 94.67%
$28.65M $30.25M $30.44M $84.33M $91.24M $52.71M $58M $25.8M $14.56M $2.69M
$55.51M $54.23M $24.3M $7.8M $5.4M $1.85M
$21.99M $20.49M $34.49M $83.41M $68.76M $54.23M
$309K $297K $188K $156K $17K $1000
$0 $194K $2.44M $4.16M
$120.71M $106.94M $82.3M $33.6M $19.96M $4.54M
$51.27M $51.1M $69.51M $173.16M $160.02M $106.94M
-$50.59M -$50.46M -$67.25M -$171.78M -$159.65M -$106.94M -$82.3M -$33.6M -$19.96M -$4.54M
-7859.97% -2967.56% -12447.97% -42572%
-$111.73M -$106.64M -$82.11M -$33.45M -$19.95M -$4.54M
$17.19M $16.98M $15.13M $13.31M $8.21M $40K $27K $20K
$998K $1.07M $2.6M $5.65M $2.53M $44K $155K
-$8.56M -$3.52M $20.17M $394K -$427K
$0 $0 $0
-$75.33M -$69.9M -$59.6M -$179.05M -$165.76M -$106.93M -$82.17M -$32.97M -$19.27M -$4.54M
-10887.38% -2630.14% -12974.86% -44201.87%
USD/shares -$5.73 -$23.51 -$98.33 -$94.72 -$64.80 -$60.64
USD/shares -$5.73 -$23.51 -$98.33 -$94.72 -$64.80 -$60.64
shares 12.21M 2.54M 1.82M 1.75M 1.65M 1.36M 1.02M 910.72K 605.31K
shares 12.21M 2.54M 1.82M 1.75M 1.65M 1.36M 1.02M 910.72K 605.31K
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2020–FY2021: $18.05M in buybacks.

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component 2025-12-31 2024-12-31 2023-12-31
Single Reportable Segment $642,000 $2,266,000 $1,380,000
Key facts CIK 1720893 CUSIP 09075P204 Visit website Investor relations